



		U.S. PAT	ENT DOCUMENTS	;		40EMAP		
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate		
Pha	6,358,944	3/19/02	Lederman et al.	514	220			
10	6,350,398	2/26/02	Breitenbach et al.	264	129			
	6,284,800	9/4/01	Broder et al.	514	652	E PE		
	6,264,917	7/24/01	Klaveness et al.	424	9.52	를 교		
	6,228,864	5/8/01	Smith et al.	514	288	ENTER I		
	6,221,368	4/24/01	Breitenbach et al.	424	400			
	6,162,467	12/19/00	Miller et al.	424	468	.200; 1600		
	6,150,424	11/21/00	Breitenbach et al.	514	772.5	2003 600/290		
	6,120,802	9/19/00	Breitenbach et al.	424	464	-8 <u> </u>		
	6,068,855	5/30/00	Leslie et al.	424	468			
	6,051,253	04/18/00	Zettler et al.	424	465			
	6,001,391	12/14/99	Zeidler et al.	424	467			
	5,980,882	11/9/99	Eichman	424	78.12			
	5,965,163	10/12/99	Miller et al.	424	468			
	5,939,099	8/17/99	Grabowski <i>et al.</i>	424	488	***		
2Mg	5,897,910	4/27/99	Rosenberg et al.	427	2.14			
		FOREIGN P	ATENT DOCUMEN	TS				
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No		
ma	EP 0 463 877	1/2/92	Europe	A61K	9/54			
RMD	WO 98/26767	6/25/98	WIPO	A61K	9/50			
U	OTHER DOCUM	ENTS (Including	Author, Title, Date	, Pertinent	Pages, Etc	;.)		
PMA	Co-pending U.S. Application No. 10/225,543, filed August 22, 2002.							
RMA	Co-pending U.S. Ap	plication No. 10/2	94,693, filed Novem	ber 15, 200	02.			
PMO	Dorow et al., Effects Nonasthmatic Chror 31(2):143-7: 1986.	of Single Oral Do nic Obstructive Lur	ses of Bisoprolol an ng Disease and Ang	d Atenolol ina Pectori	on Airway F s, <i>Eur. J. Cl</i>	unction in in. Pharmacol.,		

Page 1 of 2

RM Joyne

1/24/03

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08680.0001	Appin. No.	09/488,103	- CIPE
Applicant	Paul STARK et al.			JAN 1 3 2000 8
Filing Date	January 20, 2000	Group:	1615	E AUGO

	U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate		
PMA	Bailliart et al., Effects	of Bisoprolol on	Local Vascular Resi	stance, <i>Eu</i>	r Heart J, 8	3 Suppl M:87-93: 1987.		
	Haffner <i>et al.</i> , A Metal 6(5):397-400, 1992.	polic Assessmen	nt of The Beta₁ Selec	tivity of Bis	soprolol, J.	Hum. Hypertens.,		
	Horikiri <i>et al.</i> , Pharma 87(3): 289-294, 1998.	cokinetics and N	Metabolism of Bisopro	olol Enanti	omers in H	umans, <i>J. Pharm. Sci.</i> ,		
	Janka et al., Infludenc Dependent Diabetics,	e of Bisoprolol of J. Cardiovasc. I	on Blood Glucose, Gl Pharmacol, 8 Suppl 1	ucosuria, a 1:S96-9: 1	and Haemo 1986.	oglobin A₁ in Noninsulir		
	Kim, et al., Chiral Separation of β-Blockers after Derivatization with (-)-α-Methoxy-α- (trifluoromethyl)phenylacetyl Chloride by Gas Chromatography, Arch. Pharm. Res., 24(5):402-6, 2001. Kitaori, et al., CsF in Organic Synthesis. The First and Convenient Synthesis of Enantiopure Bisoprolo by Use of Glycidyl Nosylate, Tetrahedron Lett., 39(20), 3173-3176, 1998.							
	 Klockow <i>et al.</i>, Studies on The Receptor Profile of Bisoprolol, <i>Arzneimittelforschung</i>, 36(2):197-200, 1986. Nandel <i>et al.</i>, Conformational Structure of Some β₁-Blockers, Their Partitioning in Lipid and The Role Parasubstituents, <i>Ind. J. Biochem. Biophys.</i>, 32(4); 207-212, 1995. Nandel <i>et al.</i>, Modeling, Design, Chiral Aspects and Role of <i>Para</i>-Substituents in Aryloxypropranolamine Based β-Blockers, <i>Ind. J. Biochem. Biophys.</i>, 36(1):29-35, 1999. Schliep <i>et al.</i>, Antagonistic Effects of Bisoprolol on Several β-Adrenoceptor-Mediated Actions in Anaesthetized Cats, <i>Eur. J. Pharmacol.</i>, 123(2):253-61, 1986. 							
	Schnabel et al., Binding Properties of β -Blockers at Recobinant β_1 -, β_2 -, and β_3 -Adrenoceptors, J. Cardiovasc. Pharmacol., 36(4):466-71, 2000.							
RMA	Wellstein et al., Reduction of Exercise Tachycardia in Man after Propranolol, Atenolol and Bisoprolol in Comparison to Beta-Adrenoceptor Occupancy, Eur. Heart J., 8(Suppl. M):3-8, 1987.							
			_		<u></u>			
aminer (R)M	Joines		Date Considered	1/2	4/03	· · · · ·		

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line

Examiner:

through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce